conference programme and abstracts book - Sudanjp.org

orldHepatipro ec io•InEngeri.x"·B is a recombinant vaccine containing the surface antigen (HBsAg)of HBVat high puri~·. HBsAgitseli is non-infectious, as the infectious part ofthe rirus is its core. Exposure to HBsAg at sufficient doses provides effectiveprotection against the lirus.Clinical trials hare shown that Engerix"·B (20 ~g!dose) leads toseroconrersion in 98% of healthy adults. The immunogenicity andprorective efficacy of Engerix"·B have been confirmed in neonates,children, adolescents and adults. Anti-HBs antibodies have been shown ropersist at adequate titres for at least; years after raccination. EngerixiX.Bhas an excellent safe~' profile and is well tolerated.Engerix"'·B is arailable in dose forms containing 10 ~g or 20 ~g ofHBsAgper dose. These are recommended for children and adults. respectivel): Therelatirel)' large amounts of HBsAgin each dose hare been shown ro prorideprotection more rapidl)' and longer·lasting persistence of protecrire leve~of antibodies from HBr for normal indi\iduals than lower doses. £quallj~the recommended doses of Engerix 'W. B are beneficial for those indilidua~with a poor immune response (non·responders) due to a ranet. of factors.including older age, male gender, obesity and smoking.Immunocompromised people, such as those ~'ith renal disease or HIVinfection, need special regimens of Engerix"·B inrolring higher doses ofantigen (up ro ,,0 ~ dose), the use of which has been raJidated in clinicaltrials.Glaxo'Smithli